PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10

作者：

Xiao, Jun ^{[1
]}

Deng, Yi-Min ^{[1
]}

Liu, Xiang-Rui ^{[1
]}

Cao, Jian-Ping ^{[2
]}

Zhou, Min ^{[1
]}

Tang, Ya-Ling ^{[1
]}

Xiong, Wen-Hao ^{[1
]}

Jiang, Zhi-Sheng ^{[1
]}

Tang, Zhi-Han ^{[1
]}

Liu, Lu-Shan ^{[1
]}

机构：

[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China

[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China

来源：

CLINICA CHIMICA ACTA | 2019年 / 495卷

基金：

中国国家自然科学基金;

关键词：

Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;

D O I：

10.1016/j.cca.2019.05.005

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.

引用

页码：358 / 364

页数：7

共 50 条

[41] The mystery of PCSK9
Attie, AD
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (08) : 1337 - 1339
[42] PCSK9 IN YOUTH
Baass, A.
Dubuc, G.
Lambert, M.
Davignon, J.
ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
[43] The PCSK9 decade
Lambert, Gilles
Sjouke, Barbara
Choque, Benjamin
Kastelein, John J. P.
Hovingh, G. Kees
JOURNAL OF LIPID RESEARCH, 2012, 53 (12) : 2515 - 2524
[44] The PCSK9 story
Abifadel, Marianne
Boileau, Catherine
EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1341 - 1342
[45] PCSK9 inhibitors
Gencer, Baris
Lambert, Gilles
Mach, Francois
SWISS MEDICAL WEEKLY, 2015, 145
[46] New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide
Landmesser, Ulf
Makhmudova, Umidakhon
CIRCULATION, 2023, 148 (02) : 159 - 161
[47] PCSK9 pipeline
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (12) : 811 - 811
[48] PCSK9 pipeline
Asher Mullard
Nature Reviews Drug Discovery, 2016, 15 : 811 - 811
[49] The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi-Borojeni, Amir Abbas
Banach, Maciej
Ruscica, Massimiliano
Sahebkar, Amirhossein
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1199 - 1208
[50] PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation
Toth, Stefan
Olexa, Peter
Hertelyova, Zdenka
Stefanic, Peter
Kopolovets, Ivan
Berek, Peter
Filip, Vladimir
Chakravarty, Ryan
Siroka, Monika
Pella, Daniel
OPEN CHEMISTRY, 2020, 18 (01): : 1011 - 1019

← 1 2 3 4 5 →